Stay updated on Daratumumab & DLI for Relapsed AML Clinical Trial

Sign up to get notified when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab & DLI for Relapsed AML Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a phase I/II clinical trial involving daratumumab and donor lymphocyte infusions for treating participants with relapsed acute myeloid leukemia after stem cell transplant.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:56.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying conditions such as AML relapse following Allo-HSCT and other health requirements. Previously, this section had no information provided.
    Difference
    22%
    Check dated 2024-05-22T21:21:24.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:36:24.000Z thumbnail image

Stay in the know with updates to Daratumumab & DLI for Relapsed AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.